Approval · Notice of Compliance 516 · 2003
ESTALIS-SEQUI: Notice of Compliance 516
Issued December 30, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 516
- Date
- December 30, 2003
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update resulting from the women's health initiative (whi) study
- Therapeutic class
- Progestin-estrogen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESTALIS-SEQUI | Not yet assigned | — |
Medicinal ingredients
- ESTRADIOL 0.62 MG per PATCH
- NORETHINDRONE ACETATE 2.7 MG per PATCH
- ESTRADIOL 0.51 MG per PATCH
- NORETHINDRONE ACETATE 4.8 MG per PATCH
- ESTRADIOL 4.33 MG per PATCH